BioMedNewsBreaks Archive - Page 120 of 246

MondayMar 13, 2023 11:36 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces It Has No Exposure to Silicon Valley Bank Issues

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that it is aware that the Federal Deposit Insurance Corp. has taken control of Silicon Valley Bank (“SVB”) due to liquidity concerns. CNS Pharmaceuticals does not hold any deposits or investments at SVB. To view the full press release, visit https://ibn.fm/SPCyI About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the…

FridayMar 10, 2023 1:18 pm

BioMedNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Bringing Hope for Alzheimer’s Treatment

India Globalization Capital (NYSE American: IGC) is developing a cannabis-based investigational drug that is being tested for the first time ever on humans in an FDA-approved study. This is groundbreaking work that established its commitment as a pioneer in the treatment of Alzheimer’s disease, given there are no currently FDA-approved drugs to treat Alzheimer’s patients. “The company is developing its proprietary treatment, IGC-AD1, hoping to provide relief to the 55 million people worldwide struggling with agitation in dementia that results from Alzheimer’s. IGC is focused on revolutionizing the treatment of Alzheimer’s with its game-changing drug candidate. In phase 1 studies,…

ThursdayMar 09, 2023 12:30 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enrolls First Patient in Switzerland in Potentially Pivotal Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that the first patient in Switzerland has been enrolled in the company’s ongoing global trial. The potentially pivotal trial is focused on evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. “The active patient enrollment we continue to build across our clinical trial sites in Europe is incredibly encouraging. Our team is laser focused on getting additional clinical trial sites online so that…

WednesdayMar 08, 2023 12:47 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Makes Changes in Senior Leadership Roles

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, has made key leadership changes. The company announced that HeartBeam president Robert Eno has been appointed executive vice president while current chief business officer Jon Hunt, PhD, will transition into the role of strategic advisor and consultant, effective March 15, 2023. According to the announcement, these changes are being made ahead of key 2023 milestones, including FDA clearance for the HeartBeam AIMI(TM) system and FDA submission of the HeartBeam AIMIGo(TM) 3D vector ECG first-generation product. The…

WednesdayMar 08, 2023 12:35 pm

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Appoints Veteran of Media Industry as Chief Content, Engagement Officer

Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has announced a new chief content and engagement officer. Maureen Connolly, an award-winning content strategic and audience builder, will step into the position. According to the announcement, Connolly has 20-plus years of experience in the health, wellness, science and technology sectors. She has proven expertise in working with product, marketing, and engineering teams to create content platforms that enable and encourage engagement between businesses and global audiences while also building supportive, connected communities. “Maureen’s background, experience and passion couldn’t be better…

WednesdayMar 08, 2023 12:16 pm

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Participate at Oppenheimer 33rd Annual Health Care Conference

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today announced that its Chief Executive Officer Doug Drysdale will participate at the Oppenheimer 33rd Annual Health Care Conference taking place on March 13-15, 2023. Drysdale’s fireside chat will be webcast live on Tuesday, March 14, at 12:40 p.m. ET. Interested parties should visit https://ibn.fm/4Qlqa to register for and access the webcast. The archived version will also be available on the company’s investor relations website. To view the full press release, visit https://ibn.fm/sxkbQ About Cybin Inc. Cybin is a leading ethical biopharmaceutical company working with…

WednesdayMar 08, 2023 12:04 pm

BioMedNewsBreaks – Unicycive Therapeutics Inc. (NASDAQ: UNCY) Announces up to $130M to Commercialize and Launch Investigational New Drug

Unicycive (NASDAQ: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, has announced its entry into a securities purchase agreement with certain health care-focused institutional investors that will provide up to $130 million in gross proceeds to Unicycive through a private placement. According to the announcement, the private placement includes initial upfront funding of $30 million. Vivo Capital is leading the funding with participation from RA Capital, BVF Partners, Logos Capital, and support by existing investors Nantahala Capital Partners and Rosalind Advisors Inc. In conjunction with the financing, Gaurav Aggarwal, M.D., managing director of Vivo Capital, will…

TuesdayMar 07, 2023 12:37 pm

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Announces Clinical Trial of Jellyfish Sting Prevention Sunscreen on Man-O-War

Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair, skin, and sexual wellness, has launched a clinical trial designed to explore the effectiveness of an improved formulation of NoStingz jellyfish sting prevention sunscreen against man-o-war jellyfish. The trial, which will be led by Dr. Patric Rice and Dr. Eric Stroud, will be conducted by Angelshark Consulting; the trial will take place in the Florida Keys. The company called the launch of the trial a “milestone” and noted that the trial will be focused on evaluating the human response to stings from man-o-war jellyfish when protective sunscreen developed by Jupiter…

MondayMar 06, 2023 1:19 pm

BioMedNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Reports on Debt Settlement Agreements

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and post-traumatic stress disorder, has announced debt settlements. According to the announcement, the company announced settlements for debt owed to some arms-length creditors, service providers and debtors of the company. The company noted that the agreements call for debt to be converted into common shares in the capital of the company. The debt settlements should eliminate an estimated $752,160 of liabilities; some 1,299,998 shares were issued as a result…

MondayMar 06, 2023 12:30 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Featured ‘Test. Optimize. Scale.’ Podcast Series

BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotech company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, is spotlighted in a recent episode of the “Test. Optimize. Scale.” podcast series, which features industry leaders and pioneers sharing insights and experiences of growing their businesses to scale. BiondVax CEO Amir Reichman is a guest of the popular on-demand podcast, which is hosted by Jason Fishman, SVP Digital Strategy for Digital Niche Agency. During the podcast, Reichman talked about his journey leading up to joining BiondVax in 2021 as well as the company’s current plans, which…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces It Has No Exposure to Silicon Valley Bank Issues

BioMedNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Bringing Hope for Alzheimer’s Treatment

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Enrolls First Patient in Switzerland in Potentially Pivotal Berubicin Trial

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Makes Changes in Senior Leadership Roles

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Appoints Veteran of Media Industry as Chief Content, Engagement Officer

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Participate at Oppenheimer 33rd Annual Health Care Conference

BioMedNewsBreaks – Unicycive Therapeutics Inc. (NASDAQ: UNCY) Announces up to $130M to Commercialize and Launch Investigational New Drug

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Announces Clinical Trial of Jellyfish Sting Prevention Sunscreen on Man-O-War

BioMedNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Reports on Debt Settlement Agreements

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) CEO Featured ‘Test. Optimize. Scale.’ Podcast Series

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search